Shamburg News · 8-K filed Oct 23, 2026, 5:18 PM EDT
Traws Pharma Enters $50 Million Common Stock Purchase Agreement with Roth Principal Investments
TRAW · Traws Pharma, Inc.
- Material agreement
- Financing
- Materiality: medium
On October 23, 2026, Traws Pharma, Inc. entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Roth Principal Investments, LLC. The agreements give the Company the right, at its discretion, to sell up to $50,000,000 of newly issued common stock to Roth Principal Investments over a term tied to a registration statement's effectiveness and a 36-month period. The Company also agreed to pay certain fees, and the Purchase Agreement limits issuances above a 3,072,118-share Exchange Cap absent stockholder approval or a price condition.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 9.01, accession 0001104659-26-118519.
Written from the filing by Shamburg Markets. Figures are as reported by the company.